Plegridy, Biogen IDEC's new version of Avonex, has been delayed by the FDA. They have extended the review period without asking for additional studies. Plegridy is Avonex on a less frequent dosing schedule.
http://www.reuters.com/article/2014/03/18/biogen-fda-multiplesclerosis-idUSL3N0MF32I20140318
Kyle